Literature DB >> 35586084

ROS1-positive Inflammatory Myofibroblastic Tumor of the Small Bowel Causing Obstruction: A Case Report.

Anatoly Budylev1, Irit Solar2, Rivka Kessner1,3, Asaf Aizic2.   

Abstract

Inflammatory Myofibroblastic Tumors (IMTs) are rare fibroblastic/myofibroblastic neoplasms that affect predominately pediatric patients and young adults. Almost half of the patients with IMTs have a chromosomal abnormality in the Anaplastic Lymphoma Kinase 1 gene on chromosome 2p23. Although these tumors occur primarily in the lung, lesions have been reported in a variety of intra-abdominal organs like the liver, spleen, and mesentery. Small bowel IMTs are particularly rare. IMTs generally pursue a benign clinical course, however intra-abdominal and retroperitoneal tumors have typically shown higher local recurrence and even distant metastases. The most common presenting symptoms of an intra-abdominal IMT are abdominal pain and change in bowel habits. Laboratory results are nonspecific and can include anemia and minor elevation of inflammatory markers like C-reactive protein. We report an unusual case of IMT in the small bowel causing the obstruction. Copyright Journal of Radiology Case Reports.

Entities:  

Keywords:  Bowel solitary mast cell tumor; Inflammatory Myofibroblastic Tumor; Inflammatory pseudotumor; Small bowel obstruction; extra-pulmonary Inflammatory Myofibroblastic Tumors

Mesh:

Substances:

Year:  2022        PMID: 35586084      PMCID: PMC9063829          DOI: 10.3941/jrcr.v16i1.3928

Source DB:  PubMed          Journal:  J Radiol Case Rep        ISSN: 1943-0922


  17 in total

Review 1.  Inflammatory myofibroblastic tumor of the small intestine.

Authors:  John W Difiore; John R Goldblum
Journal:  J Am Coll Surg       Date:  2002-04       Impact factor: 6.113

2.  Bilateral renal inflammatory pseudotumour effectively treated with corticosteroid.

Authors:  Jordan Yuanzhi Li; Tuck Y Yong; Mark Coleman; David Astill; George Passaris; Rajiv Juneja; Mark Siddins; Jeffrey A J Barbara
Journal:  Clin Exp Nephrol       Date:  2009-11-18       Impact factor: 2.801

3.  Inflammatory myofibroblastic tumor: FDG PET/CT findings with pathologic correlation.

Authors:  Aisheng Dong; Yang Wang; Hui Dong; Jing Gong; Chao Cheng; Changjing Zuo; Jianping Lu
Journal:  Clin Nucl Med       Date:  2014-02       Impact factor: 7.794

4.  Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.

Authors:  Jason L Hornick; Lynette M Sholl; Paola Dal Cin; Merrida A Childress; Christine M Lovly
Journal:  Mod Pathol       Date:  2015-01-23       Impact factor: 7.842

5.  Inflammatory myofibroblastic tumors in children.

Authors:  Brian G A Dalton; Priscilla G Thomas; Nicole E Sharp; Michelle A Manalang; James E Fisher; Christopher R Moir; Shawn D St Peter; Corey W Iqbal
Journal:  J Pediatr Surg       Date:  2015-11-27       Impact factor: 2.545

6.  The pulmonary plasma cell/histiocytoma complex.

Authors:  H Spencer
Journal:  Histopathology       Date:  1984-11       Impact factor: 5.087

7.  ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.

Authors:  Hidetaka Yamamoto; Akihiko Yoshida; Kenichi Taguchi; Kenichi Kohashi; Yui Hatanaka; Atsushi Yamashita; Daisuke Mori; Yoshinao Oda
Journal:  Histopathology       Date:  2016-01-19       Impact factor: 5.087

8.  Inflammatory myofibroblastic tumours: a pictorial review.

Authors:  Jon Etxano Cantera; María Páramo Alfaro; David Cano Rafart; Romina Zalazar; Maite Millor Muruzabal; Paula García Barquín; Isabel Vivas Pérez
Journal:  Insights Imaging       Date:  2014-12-18

9.  Inflammatory myofibroblastic tumor of the small-bowel mesentery: A case report of nonspecific clinical presentation and a review of the literature.

Authors:  Ali Koyuncuer
Journal:  Int J Surg Case Rep       Date:  2014-11-20

10.  Retroperitoneal inflammatory myofibroblastic tumor: A case report.

Authors:  Oliveira Carlos; Costa Rui; Estêvão Amélia; Caseiro-Alves Filipe
Journal:  Eur J Radiol Open       Date:  2017-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.